News: Teva Pharmaceutical Industries Ltd (TEVA.N)

TEVA.N on New York Stock Exchange

56.47USD
4:06pm EDT
Price Change (% chg)

$0.00 (+0.00%)
Prev Close
$56.47
Open
$57.00
Day's High
$57.00
Day's Low
$55.92
Volume
751,539
Avg. Vol
603,810
52-wk High
$57.00
52-wk Low
$36.26

Search Stocks
Select another date:

Thu, Oct 30 2014

Teva raises 2014 profit forecast after strong third quarter

TEL AVIV - Teva Pharmaceutical Industries reported stronger than expected third-quarter profits due to improved profitability for its generic medicines, and was hopeful of keeping patent protection for best-selling drug Copaxone.

UPDATE 2-Teva raises 2014 profit forecast after strong third quarter

* Raises 2014 EPS outlook to $5.00-$5.10 from pvs $4.90-$5.10

Teva optimistic U.S. top court to rule in favor of MS drug patent

TEL AVIV - Teva Pharmaceutical Industries is optimistic the U.S. Supreme Court will decide in its favor regarding patent protection for Copaxone, its multiple sclerosis treatment, Chief Executive Erez Vigodman said on Thursday.

Teva optimistic U.S. top court to rule in favour of MS drug patent

TEL AVIV, Oct 30 - Teva Pharmaceutical Industries is optimistic the U.S. Supreme Court will decide in its favour regarding patent protection for Copaxone, its multiple sclerosis treatment, Chief Executive Erez Vigodman said on Thursday.

Teva Pharm Q3 profit beats estimates, raises 2014 EPS forecast

TEL AVIV, Oct 30 - Teva Pharmaceutical Industries reported quarterly profit that beat analysts' estimates on Thursday and raised its earnings forecast for the full year.

UPDATE 2-U.S. top court divided in battle over Teva MS drug patent

(Adds fresh details from oral argument, paragraphs 8-9, 11-12)

U.S. Supreme Court justices divided over Teva patent battle

WASHINGTON, Oct 15 - The U.S. Supreme Court on Wednesday appeared closely divided as it weighed Teva Pharmaceutical Industries Ltd's high-profile fight with generic drug manufacturers over patent protections for Copaxone, its top-selling multiple sclerosis drug.

U.S. top court hears Teva's multiple sclerosis drug patent fight

WASHINGTON - The U.S. Supreme Court on Wednesday is set to wade into Teva Pharmaceutical Industries Ltd's fight over patent protections for Copaxone, its top-selling multiple sclerosis drug, in one of the most important business cases of the justices' new term.

U.S. top court hears Teva's multiple sclerosis drug patent fight

WASHINGTON, Oct 15 - The U.S. Supreme Court on Wednesday is set to wade into Teva Pharmaceutical Industries Ltd's fight over patent protections for Copaxone, its top-selling multiple sclerosis drug, in one of the most important business cases of the justices' new term.

Actavis to buy Durata in a deal valued at about $675 million

- Generic drugmaker Actavis Plc said it would acquire Durata Therapeutics Inc in a deal valued at about $675 million to bolster its infectious disease portfolio.

Select another date:
Search Stocks